Meta-Analysis: The Efficacy and Safety of Paricalcitol for the Treatment of Secondary Hyperparathyroidism and Proteinuria in Chronic Kidney Disease

Figure 1

Comparison of the probability of achieving ≥30% decrease in iPTH from baseline for two consecutive measures.